메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제50권 제3호
발행연도
2020.1
수록면
295 - 307 (13page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background The bioactive sphingolipids such as ceramide, sphingosine, and sphingosine-1-phosphate are of special interest as key regulators of cellular proliferation or apoptosis signaling. The balance between ceramide and sphingosine-1-phosphate is critical for the selection of proliferative or apoptotic signaling as well as for therapeutic efficacy against cancer cells. Area covered A number of drug candidates designed to regulate the balance between ceramide and sphingosine-1-phosphate have been developed and several (i.e., safingol, ABC294640, Sonepcizumab, and fingolimod) are under clinical investigation as anti-cancer drugs. Various nanotherapeutic challenges combined with the use of anticancer drugs and/or phospholipid metabolism inhibitors and short chain ceramide has been investigated to increase the cellular accumulation of ceramide, which acts as apoptotic signaling molecules. Expert opinion Many sphingolipid-containing nanotherapeutics have shown promising results as cancer treatments. These sphingolipid nanotherapeutics can include a synergistic combination of short chain ceramide and ceramide-forming anticancer agents or sphingolipid metabolism inhibitors. Sphingolipid nanotherapeutics could also be used to treat multidrug-resistant cancer cells as well as sensitive cancer cells.

목차

등록된 정보가 없습니다.

참고문헌 (86)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0